Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis
- 4 November 2024
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (12) , 3849-3853
Abstract
Introduction The most frequent adverse events (AEs) of methotrexate (MTX) are gastrointestinal symptoms and hepatotoxicity, which can affect its adherence, leading to reduced effectiveness. The SLCO1B1 gene codes for a liver protein (OATP1B1) responsible for drug transportation. Genetic variations within the SLCO1B1 gene locus impact drug transport, leading to altered pharmacokinetic profiles, delayed MTX clearance, and increased risk of toxicity. This study aimed to determine the association between single nucleotide polymorphisms (SNPs) in the SLCO1B1 gene (rs4149056, rs2306283) with the development of AEs in patients with juvenile idiopathic arthritis (JIA) treated with MTX. Method We performed an observational retrospective study to analyze the relationship between SNPs in the SLCO1B1 gene and the development of AEs in pediatric patients treated with MTX for JIA. Results Thirty patients with JIA were included, 22 females (73.3%), with a median age of 11 years (IQR 8.3–15). The most frequent JIA subtype was rheumatoid factor-positive polyarthritis (36.7%). Twenty patients (66.7%) reported AEs. The *1B haplotype was the most frequent in this group (53.3%) and conferred a higher risk of developing AEs (OR = 3.89, 95% CI = 1.23 -12.29, p = 0.03). Conclusions Patients with the allele *1B may benefit from lower doses of MTX. SLCO1B1 genotyping is a promising technique to identify patients at higher risk of AEs during treatment with MTX, thus requiring dose optimization. Key Points • The most frequent SLCO1B1 haplotype in our population was *1B, also associated with a higher risk of developing adverse events (OR=3.89, 95% CI=1.23 -12.29, p=0.03). • SLCO1B1 genotyping is a promising tool to help identify patients at higher risk of MTX-related AEs.Keywords
This publication has 12 references indexed in Scilit:
- Prevalence of Protective Haplotypes of the SLCO1B1 Gene for Statin Transport in Mexican PopulationsPersonalized Medicine, 2021
- SLCO1B1variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritisScandinavian Journal of Rheumatology, 2021
- Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritisPediatric Rheumatology, 2021
- Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patientsThe Pharmacogenomics Journal, 2019
- Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meetingPediatric Rheumatology, 2018
- Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the ModelsFrontiers in Pharmacology, 2018
- Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature reviewPediatric Rheumatology, 2014
- Admixture in Latin America: Geographic Structure, Phenotypic Diversity and Self-Perception of Ancestry Based on 7,342 IndividualsPLOS Genetics, 2014
- SLC19A1, SLC46A1 and SLCO1B1 Polymorphisms as Predictors of Methotrexate-Related Toxicity in Portuguese Rheumatoid Arthritis PatientsToxicological Sciences, 2014
- Genome-wide study of methotrexate clearance replicates SLCO1B1Blood, 2013